Preventable Deaths among HIV-Positive Patients: A Real-Life Perspective from a Teaching Hospital in Northern Mexico
DOI:
https://doi.org/10.17140/HARTOJ-5-128Keywords:
HIV/AIDS therapy, Tuberculosis, Mortality, MéxicoAbstract
Introduction
Antiretroviral therapy (ART) in patients infected with human immunodeficiency virus (HIV) are more effective and better tolerated and for this reason the gap between life expectancy of an HIV-seropositive individual and a seronegative one has been closing. This study was carried out to identify the main causes of death in in HIV-infected patients in a tertiary-care hospital as well as relevant sociodemographic and clinical factors that contribute to their prognosis.
Aim
The aim of the present study is to identify the main causes of death in HIV/AIDS patients as well as relevant sociodemographic and clinical factors that contribute to their prognosis.
Methods
A retrospective cohort was conducted with confirmed HIV-infected adult patients who died between January 2010 and January 2017. Sociodemographic and clinical data were taken from their clinical records to carry out a statistical analysis on the mortality of these patients and the relevant factors that contributed.
Results
A total of 120 patients with in-hospital mortality and HIV diagnosis were included, of these, 55% were allocated to an AIDS defining event, 75.8% had an HIV diagnosis of less than 6 months from their death, 88.3% received HIV testing for suspicion or confirmation of an AIDS defining event, and 50% had two or more active AIDS defining events at admission.
Conclusion
A major public health concern is a late HIV/AIDS diagnosis, a situation that is occurring in Mexico. Despite universal access to antiretroviral treatment, the most common causes of mortality in HIV-positive patients are still AIDS defining events, mainly tuberculosis and other opportunistic infections that with a prompt diagnosis might have been prevented if these patients had initiated early antiretroviral therapy.
References
Samji H, Cescon A, Hogg RS, et al. Closing the gap: Increases in life expectancy among treated HIV-positive individuals in the United States and Canada. PLoS One. 2013; 8(12): e81355. doi: 10.1371/journal.pone.0081355
Cheung CC, Ding E, Sereda P, et al. Reductions in all-cause and Retrospective Study | Volume 5 | Number 1| Ortiz AC, et al cause-specific mortality among HIV-infected individuals receiv-ing antiretroviral therapy in British Columbia, Canada: 2001-2012. HIV Med. 2016; 17(9): 694-701. doi: 10.1111/hiv.12379
Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodefi-ciency virus infection. HIV outpatient study investigators. N Engl J Med.1998; 338(13): 853-860. doi: 10.1056/nejm199803263381301
Hernandez-Romieu AC, Del Rio C, Hernandez-Avila JE, et al. CD4 Counts at entry to HIV care in Mexico for patients under the "universal antiretroviral treatment program for the uninsured population," 2007-2014. PLoS One. 2016; 11(3): e0152444. doi: 10.1371/journal.pone.015244
Pineirua A, Sierra-Madero J, Cahn P, et al. The HIV care con-tinuum in Latin America: Challenges and opportunities. Lancet In-fect Dis. 2015; 15(7): 833-839. doi: 10.1016/s1473-3099(15)00108-5
Silverman-Retana O, Bautista-Arredondo S, Servan-Mori E, Lo-zano R. AIDS-related early mortality in Mexico between 2008 and 2012. Salud Publica Mex. 2015; 57 Suppl 2: s119-126.
Baez-Saldana R, Villafuerte-Garcia A, Cruz-Hervert P, et al. As-sociation between highly active antiretroviral therapy and type of infectious respiratory disease and all-cause in-hospital mortality in patients with HIV/AIDS: A case series. PLoS One. 2015; 10(9): e0138115. doi: 10.1371/journal.pone.0138115
Kitahata MM, Gange SJ, Abraham AG, et al. Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med. 2009; 360(18): 1815-1826. doi: 10.1056/NEJMoa0807252
Mugavero MJ, Davila JA, Nevin CR, Giordano TP. From ac-cess to engagement: measuring retention in outpatient HIV clinical care. AIDS Patient Care STDS. 2010; 24(10): 607-613. doi: 10.1089/ apc.2010.0086
Sabin CA, Howarth A, Jose S, Hill T, et al. Association between engagement in-care and mortality in HIV-positive persons. AIDS. 2017; 31(5): 653-660. doi: 10.1097/qad.0000000000001373
Collier AC, Coombs RW, Schoenfeld DA, et al. Treatment of human immunodeficiency virus infection with saquinavir, zid-ovudine, and zalcitabine. AIDS clinical trials group. N Engl J Med. 1996; 334(16): 1011-1017. doi: 10.1056/nejm199604183341602
Horberg MA, Silverberg MJ, Hurley LB, et al. Effects of de-pression and selective serotonin reuptake inhibitor use on adher-ence to highly active antiretroviral therapy and on clinical outcomes in HIV-infected patients. J Acquir Immune Defic Syndr. 2008; 47(3): 384-390. doi: 10.1097/QAI.0b013e318160d53e
Tegger MK, Crane HM, Tapia KA, Uldall KK, Holte SE, Ki-tahata MM. The effect of mental illness, substance use, and treat-ment for depression on the initiation of highly active antiretroviral therapy among HIV-infected individuals. AIDS Patient Care STDS. 2008; 22(3): 233-243. doi: 10.1089/apc.2007.0092
Lesko CR, Todd JV, Cole SR, et al. Mortality under plausible interventions on antiretroviral treatment and depression in HIV-infected women: An application of the parametric g-formula. Ann Epidemiol. 2017; 27(12): 783-789.e782. doi: 10.1016/j.annepi-dem.2017.08.021
Hoots BE, Torrone EA, Bernstein KT, Paz-Bailey G. Self-re-ported chlamydia and gonorrhea testing and diagnosis among men who have sex with Men-20 US cities, 2011 and 2014. Sex Transm Dis. 2018; 45(7): 469-475. doi: 10.1097/olq.0000000000000786
Selwyn PA, Sckell BM, Alcabes P, Friedland GH, Klein RS, Schoenbaum EE. High risk of active tuberculosis in HIV-infected drug users with cutaneous anergy. JAMA. 1992; 268(4): 504-509. doi: 10.1001/jama.268.4.504
Cain KP, McCarthy KD, Heilig CM, et al. An algorithm for tuberculosis screening and diagnosis in people with HIV. N Engl J Med. 2010; 362(8): 707-716. doi: 10.1056/NEJMoa0907488
Djawe K, Buchacz K, Hsu L, et al. Mortality risk after AIDS-defining opportunistic illness among HIV-infected persons--san francisco, 1981-2012. J Infect Dis. 2015; 212(9): 1366-1375. doi: 10.1093/infdis/jiv235
Mocroft A, Sterne JA, Egger M,et al. Variable impact on mor-tality of AIDS-defining events diagnosed during combination an-tiretroviral therapy: Not all AIDS-defining conditions are created equal. Clin Infect Dis. 2009; 48(8): 1138-1151. doi: 10.1086/597468
Crabtree-Ramirez B, Caro-Vega Y, Shepherd BE, et al. Time to HAART initiation after diagnosis and treatment of opportunistic infections in patients with AIDS in Latin America. PLoS One. 2016; 11(6): e0153921. doi: 10.1371/journal.pone.0153921
Martin-Onraet A, Pineirua-Menendez A, Perales-Martinez D, et al. In-hospital mortality in HIV-infected patients: 10 years af-ter the implementation of universal access to HAART in Mexico. Salud Publica Mex. 2015; 57 Suppl 2: s163-170.
Kabudula CW, Houle B, Collinson MA, et al. Socioeconomic differences in mortality in the antiretroviral therapy era in agin-court, rural South Africa, 2001-13: A population surveillance analysis. Lancet Glob Health. 2017; 5(9): e924-e935. doi: 10.1016/ s2214-109x(17)30297-8 Submit your article to this journal | https://openventio.org/submit-manuscript/
Ellis PK, Martin WJ, Dodd PJ. CD4 count and tuberculosis risk in HIV-positive adults not on ART: A systematic review and meta-analysis. PeerJ. 2017; 5: e4165. doi: 10.7717/peerj.4165
Day JH, Charalambous S, Fielding KL, Hayes RJ, Churchyard GJ, Grant AD. Screening for tuberculosis prior to isoniazid pre-ventive therapy among HIV-infected gold miners in South Africa. Int J Tuberc Lung Dis. 2006; 10(5): 523-529.
Selwyn PA, Hartel D, Lewis VA, et al. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N Engl J Med. 1989; 320(9): 545- 550. doi: 10.1056/nejm198903023200901
1993 Revised classification system for HIV infection and ex-panded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep. 1992; 41(RR-17): 1-19.
Braitstein P, Brinkhof MW, Dabis F, et al. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: Com-parison between low-income and high-income countries. Lancet. 2006; 367(9513): 817-824. doi: 10.1016/s0140-6736(06)68337-2
Bravo-Garcia E, Ortiz-Perez H. Analysis of HIV/AIDS mor-tality in Mexico from 1990 to 2013: An assessment of the feasibil-ity of millennium development goals by 2015. Gac Med Mex. 2016; 152(6): 819-830.
Freiberg MS, Chang CC, Kuller LH, et al. HIV infection and the risk of acute myocardial infarction. JAMA Intern Med. 2013; 173(8): 614-622. doi: 10.1001/jamainternmed.2013.3728
Cerrato E, Calcagno A, D'Ascenzo F, et al. Cardiovascular dis-ease in HIV patients: From bench to bedside and backwards. Open Heart. 2015; 2(1): e000174. doi: 10.1136/openhrt-2014-000174
Marcus JL, Leyden WA, Chao CR, et al. HIV infection and incidence of ischemic stroke. AIDS. 2014; 28(13): 1911-1919. doi: 10.1097/qad.0000000000000352
Butt AA, Chang CC, Kuller L, et al. Risk of heart failure with human immunodeficiency virus in the absence of prior diagnosis of coronary heart disease. Arch Intern Med. 2011; 171(8): 737-743. doi: 10.1001/archinternmed.2011.151
Flores-Trevino S, Mendoza-Olazaran S, Garza-Gonzalez E. Drug resistance and molecular epidemiology of Mycobacterium tuberculosis in Mexico: A systematic review. Salud Publica Mex. 2014; 56(1): 63-77. doi: 10.21149/spm.v56i1.7324
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content published in HIV/AIDS Research and Treatment (HRT) is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows anyone to copy, distribute, transmit, and adapt the work — including for commercial purposes — provided appropriate credit is given to the original author(s) and source.
